Long-term benefits of omalizumab in a patient with severe non-allergic asthma

INTRODUCTION: Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy. CASE PRESENTATION: We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Menzella, Francesco, Piro, Roberto, Facciolongo, Nicola, Castagnetti, Claudia, Simonazzi, Anna, Zucchi, Luigi
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2011
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3126749/
https://ncbi.nlm.nih.gov/pubmed/21609447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1710-1492-7-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky